Search Results - "VARAINE, F"

The low void worth core design (‘CFV’) based on an axially heterogeneous geometry by Sciora, P., Buiron, L., Varaine, F.

“…•A fast core design with a negative sodium void worth and with comparable performances with a homogeneous core.•Physical explanations of the different…”
Get full text

Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia by Hewison, C., Bastard, M., Khachatryan, N., Kotrikadze, T., Hayrapetyan, A., Avaliani, Z., Kiria, N., Yegiazaryan, L., Chumburidze, N., Kirakosyan, O., Atshemyan, H., Qayyum, S., Lachenal, N., Varaine, F., Huerga, H.

“…BACKGROUND AND SETTING: Bedaquiline (BDQ) was initially only available through compassionate use programmes.OBJECTIVE: To assess the effectiveness and safety…”
Get full text

What will it take to eliminate drug-resistant tuberculosis? by Kendall, E. A., Sahu, S., Pai, M., Fox, G. J., Varaine, F., Cox, H., Cegielski, J. P., Mabote, L., Vassall, A., Dowdy, D. W.

“…Drug-resistant tuberculosis (DR-TB) is challenging to diagnose, treat, and prevent, but this situation is slowly changing. If the world is to drastically…”
Get full text

Thin-Layer-Agar-Based Direct Phenotypic Drug Susceptibility Testing on Sputum in Eswatini Rapidly Detects Mycobacterium tuberculosis Growth and Rifampicin Resistance Otherwise Missed by WHO-Endorsed Diagnostic Tests by Ardizzoni, E, Ariza, E, Mulengwa, D, Mpala, Q, de La Tour, R, Maphalala, G, Varaine, F, Kerschberger, B, Graulus, P, Page, A L, Niemann, S, Dreyer, V, Van Deun, A, Decroo, T, Rigouts, L, de Jong, B C

“…Xpert MTB/RIF rapidly detects resistance to rifampicin (RR); however, this test misses I491F-RR conferring mutation, common in southern Africa. In addition,…”
Get full text

Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study by Bonnet, M., Bastard, M., du Cros, P., Khamraev, A., Kimenye, K., Khurkhumal, S., Hayrapetyan, A., Themba, D., Telnov, A., Sanchez-Padilla, E., Hewison, C., Varaine, F.

“…BACKGROUND: The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four…”
Get full text

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications by Rich, M. L., Khan, U., Zeng, C., LaHood, A., Franke, M. F., Atwood, S., Bastard, M., Burhan, E., Danielyan, N., Dzhazibekova, P. M., Gadissa, D., Ghafoor, A., Hewison, C., Islam, M. S., Kazmi, E., Khan, P. Y., Lecca, L., Maama, L. B., Melikyan, N., Naing, Y. Y., Philippe, K., Saki, N. A., Seung, K. J., Skrahina, A., Tefera, G. B., Varaine, F., Vilbrun, S. C., Võ, L., Mitnick, C. D., Huerga, H., on behalf of the endTB Observational Study Team

“…BACKGROUND: Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB)…”
Get full text

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB by Zeng, C., Mitnick, C. D., Hewison, C., Bastard, M., Khan, P., Seung, K. J., Rich, M. L., Atwood, S., Melikyan, N., Morchiladze, N., Khachatryan, N., Khmyz, M., Restrepo, C. G., Salahuddin, N., Kazmi, E., Dahri, A. A., Ahmed, S., Varaine, F., Vilbrun, S. C., Oyewusi, L., Gelin, A., Tintaya, K., Yeraliyeva, L. T., Hamid, S., Khan, U., Huerga, H., Franke, M. F.

“…BACKGROUND: The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these…”
Get full text

Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study by Sanchez-Padilla, E., Marquer, C., Kalon, S., Qayyum, S., Hayrapetyan, A., Varaine, F., Bastard, M., Bonnet, M.

“…SETTING: Armenia, a country with a high prevalence of drug-resistant tuberculosis (DR-TB).OBJECTIVE: To identify factors related to default from DR-TB…”
Get full text

(Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis by Milstein, M., Brzezinski, A., Varaine, F., Mitnick, C. D.

“…BACKGROUND: Currently recommended regimens for multidrug-resistant tuberculosis (MDR-TB) contain painful daily injections and are unsuccessful in approximately…”
Get full text

What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis? by Bastard, M., Sanchez-Padilla, E., Hayrapetyan, A., Kimenye, K., Khurkhumal, S., Dlamini, T., Fadul Perez, S., Telnov, A., Hewison, C., Varaine, F., Bonnet, M.

“…INTRODUCTION: Identification of good prognostic marker for tuberculosis (TB) treatment response is a necessary step on the path towards a surrogate marker to…”
Get full text

Outcomes from the first multidrug-resistant tuberculosis programme in Kenya by Huerga, H., Bastard, M., Kamene, M., Wanjala, S., Arnold, A., Oucho, N., Chikwanha, I., Varaine, F.

“…SETTING: In March 2006, the first multidrug-resistant tuberculosis (MDR-TB) treatment programme was implemented in Kenya.OBJECTIVE: To describe patients'…”
Get full text

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial by Guglielmetti, L, Ardizzoni, E, Atger, M, Baudin, E, Berikova, E, Bonnet, M, Chang, E, Cloez, S, Coit, J. M, Cox, V, de Jong, B. C, Delifer, C, Do, J. M, Tozzi, D. Dos Santos, Ducher, V, Ferlazzo, G, Gouillou, M, Khan, A, Khan, U, Lachenal, N, LaHood, A. N, Lecca, L, Mazmanian, M, McIlleron, H, Moschioni, M, O'Brien, K, Okunbor, O, Oyewusi, L, Panda, S, Patil, S. B, Phillips, P. P. J, Pichon, L, Rupasinghe, P, Rich, M. L, Saluhuddin, N, Seung, K. J, Tamirat, M, Trippa, L, Cellamare, M, Velásquez, G. E, Wasserman, S, Zimetbaum, P. J, Varaine, F, Mitnick, C. D

“…Abstract Background Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial…”
Get full text

Setting up pharmacovigilance based on available endTB Project data for bedaquiline by Lachenal, N., Hewison, C., Mitnick, C., Lomtadze, N., Coutisson, S., Osso, E., Ahmed, S., Leblanc, G., Islam, S., Atshemyan, H., Nair, P., Kholikulov, B., Aiylchiev, S., Zarli, K., Adnan, S., Krisnanda, A., Padayachee, S., Stambekova, A., Sahabutdinova, Y., de Guadalupe, S., Moreno, Perea, Kumsa, A., Reshid, A., Makaka, J., Abebe, S., Melikyan, N., Seung, K. J., Khan, U., Khan, P., Huerga, H., Rich, M., Varaine, F.

“…SETTING: Active pharmacovigilance (PV) is recommended for TB programmes, notably for multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched…”
Get full text

Introducing new and repurposed TB drugs: the endTB experience by Seung, K. J., Khan, U., Varaine, F., Ahmed, S., Bastard, M., Cloez, S., Damtew, D., Franke, M. F., Herboczek, K., Huerga, H., Islam, S., Karakozian, H., Khachatryan, N., Kliesckova, J., Khan, A. J., Khan, M., Khan, P., Kotrikadze, T., Lachenal, N., Lecca, L., Lenggogeni, P., Maretbayeva, S., Melikyan, N., Mesic, A., Mitnick, C. D., Mofolo, M., Perrin, C., Richard, M., Tassew, Y. M., Telnov, A., Vilbrun, S. C., Wanjala, S., Rich, M. L., Hewison, C.

“…In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs…”
Get full text

The thin-layer agar method for direct phenotypic detection of multi- and extensively drug-resistant tuberculosis by Ardizzoni, E., Mulders, W., Kotrikadze, T., Aspindzelashvili, R., Goginashvili, L., Pangtey, H., Varaine, F., Bastard, M., Rigouts, L., de Jong, B. C.

“…BACKGROUND: Molecular techniques rapidly detect resistance to rifampicin (RMP) and isoniazid (INH), but do not eliminate the need for culture-based drug…”
Get full text

Impact of introducing human immunodeficiency virus testing, treatment and care in a tuberculosis clinic in rural Kenya by Huerga, H, Spillane, H, Guerrero, W, Odongo, A, Varaine, F

“…SETTING: In July 2005, Médecins Sans Frontières and the Ministry of Health, Kenya, implemented an integrated tuberculosis-human immunodeficiency virus (TB-HIV)…”
Get full text

Routine use of Xpert® MTB/RIF in areas with different prevalences of HIV and drug-resistant tuberculosis by Page, A-L., Ardizzoni, E., Lassovsky, M., Kirubi, B., Bichkova, D., Pedrotta, A., Lastrucci, C., de la Tour, R., Bonnet, M., Varaine, F.

“…SETTING: Despite the widespread introduction of Xpert® MTB/RIF in developing countries, reports of its use and value in routine conditions remain…”
Get full text

Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis [Review article] by Horsburgh, C. R. Jr, Haxaire-Theeuwes, M., Lienhardt, C., Wingfield, C., McNeeley, D., Pyne-Mercier, L., Keshavjee, S., Varaine, F., Research Excellence to Stop TB Resistance (RESIST-TB) and the Critical Path to TB Drug Regimens' Access and Appropriate Use Workgroup

“…Several new classes of anti-tuberculosis agents are likely to become available in the coming decade. Ensuring prompt access to these drugs for patients without…”
Get full text

Decontamination methods for samples preserved in cetylpyridinium chloride and cultured on thin-layer agar by Ardizzoni, E., Mulders, W., Sanchez-Padilla, E., Varaine, F., de Jong, B. C., Rigouts, L.

“…SETTING: Long transportation times of samples to culture laboratories can lead to higher contamination rates and significant loss of viability, resulting in…”
Get full text

Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions by Sanchez-Padilla, E., Ardizzoni, E., Sauvageot, D., Ahoua, L., Martin, A., Varaine, F., Adatu-Engwau, F., Akeche, G., Salaniponi, F., Bonnet, M.

“…SETTING: Despite major progress in the surveillance of drug-resistant tuberculosis (TB), data are lacking for many low-resource countries. World Health…”
Get full text